I tend to agree with you regarding the reverse split outcomes, but this stock is riding on the Flash R and maybe Nunchi, both which likely will see their make or break moment this next year.

Given EDIG pulls through, it seems to me the R/S is worth considering. Like I said, should the patents not sustain the company, none of this matters. I bought primarily for the patent portfolio and the markets they target, which ended up being as big, if not bigger than imagined.

That still is the draw, but given the Markman, the markers have changed. I look for a big upside from these levels if EDIG/DM performs via the reexam, and if Nunally can deliver Nunchi to market.